Almirall SA traded at 12.88 this Friday February 6th, decreasing 0.16 or 1.23 percent since the previous trading session. Looking back, over the last four weeks, Almirall lost 5.15 percent. Over the last 12 months, its price rose by 42.32 percent. Looking ahead, we forecast Almirall SA to be priced at 12.28 by the end of this quarter and at 11.32 in one year, according to Trading Economics global macro models projections and analysts expectations.
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.